Synagis Re-Treatment Patients Represent 21% Of Use, MedImmune Says
Executive Summary
Re-treatment with Synagis made up approximately 21% of MedImmune's sales of the monoclonal antibody product during last year's respiratory syncytial virus season.
You may also be interested in...
HPV Vaccine Accelerated Approval May Affect Safety Data Collection
The use of accelerated approval for human papilloma virus vaccines could compromise adequate collection of safety data, members of FDA's Vaccines & Related Biological Products Advisory Committee asserted at a Nov. 29 meeting in Bethesda, Md
HPV Vaccine Accelerated Approval May Affect Safety Data Collection
The use of accelerated approval for human papilloma virus vaccines could compromise adequate collection of safety data, members of FDA's Vaccines & Related Biological Products Advisory Committee asserted at a Nov. 29 meeting in Bethesda, Md
MedImmune Synagis (correction)
Reconstitution of MedImmune's Synagis (palivizumab) should be done with sterile water, not saline (1"The Pink Sheet" Oct. 15, p. 24)